Clinical Trials Logo

Tuberculosis clinical trials

View clinical trials related to Tuberculosis.

Filter by:

NCT ID: NCT02481726 Completed - Lung Cancer Clinical Trials

68Ga-AlfatideII for the Differential Diagnosis of of Lung Cancer and Lung Tuberculosis by PET/CT

Start date: March 2014
Phase: Phase 1/Phase 2
Study type: Interventional

Comparison of 68Ga-AlfatideII and 18F-FDG in differential diagnosis effectiveness towards the solitary pulmonary nodules of lung cancer or tuberculosis.

NCT ID: NCT02477852 Recruiting - Clinical trials for Tuberculosis, Spinal

The Optimal Duration of Preoperative Anti-tuberculosis Treatment of Spinal Tuberculosis

Start date: April 2015
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine the better preoperative anti-tuberculosis treatment period of patients with spinal tuberculosis.

NCT ID: NCT02467608 Completed - Clinical trials for Pulmonary Tuberculosis

Efficacy of HUEXC030 in Subjects With Pulmonary Tuberculosis

Start date: December 6, 2012
Phase: Phase 2/Phase 3
Study type: Interventional

Assess the Efficacy of HUEXC030 as Add-on Excipient to Eradicate Anti-Tuberculosis Drugs Induced Hepatic Injury ( ATDH ) in Subjects with Pulmonary Tuberculosis

NCT ID: NCT02465216 Completed - Clinical trials for Pulmonary Tuberculosis

Phase 2a ID93 + GLA-SE Vaccine Trial in TB Patients After Treatment Completion

Start date: June 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and immunogenicity of ID93 + GLA-SE vaccine when administered to adult pulmonary Tuberculosis (TB) patients, following successful completion of TB treatment with confirmed bacteriologic cure, in preparation for a future Phase 2b prevention of TB recurrence trial in the same population.

NCT ID: NCT02464683 Recruiting - Clinical trials for Pulmonary Tuberculosis

Effect of Vitamin D as Adjunctive Therapy in Patients With Pulmonary Evolution Tuberculosis

VitaminD
Start date: April 2014
Phase: Phase 4
Study type: Interventional

Tuberculosis (TB) is the second largest infectious disease that causes death in the last 4 centuries in all the world. Observational studies found an association between vitaminD and TB, suggesting a potential therapeutic role of vitaminD supplementation in patients with active tuberculosis. The hypothesis is that the administration of vitaminD is associated with changes in the levels of cytokines in patients with tuberculosis treated with first-line drugs. The aim of this study is to evaluate the effect of vitaminD supplementation on the clinical course, the time of negative smears and cultures, and the effect on the immune response in patients with pulmonary tuberculosis (TBP).

NCT ID: NCT02457208 Completed - Tuberculosis Clinical Trials

PK Study of Anti-TB Drugs

Start date: July 7, 2015
Phase: Phase 1
Study type: Interventional

This is a prospective descriptive and pharmacokinetic study will be conducted among newly diagnosed patients registered in the two SMRU TB clinics located on the Thai-Myanmar border. This study aims to recruit (1) 30 adults with HIV co-infection and (2) 30 adults without HIV co-infection in one year. Patients will be given the standard 6 month anti-TB drugs as per WHO guidelines.

NCT ID: NCT02454738 Completed - Latent Tuberculosis Clinical Trials

Ultralow Dose Computed Tomography in High-risk Drug-resistant Tuberculosis Contacts

Start date: June 2015
Phase: N/A
Study type: Interventional

To evaluate CT abnormalities in the lung parenchyma in close contacts at high risk for developing multidrug- or extensively drug-resistant Tb by using a follow-up ultralow dose CT scan.

NCT ID: NCT02454569 Recruiting - HIV Clinical Trials

Vicente Ferrer HIV Cohort Study

VFHCS
Start date: September 2009
Phase:
Study type: Observational [Patient Registry]

The VFHCS is a long-term prospective cohort study of HIV infected patients from a resource-poor rural setting in India. The aim of the study is to use data collected from routine clinical care in order to describe the epidemiology of HIV and its related conditions in the investigators area, and to study the effectiveness of health interventions in a "real-world" setting (implementation and operational research).

NCT ID: NCT02454205 Completed - Tuberculosis Clinical Trials

An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis

NEXT
Start date: November 12, 2015
Phase: Phase 2/Phase 3
Study type: Interventional

This study aims to evaluate the impact of a new injection-free six-to-nine month treatment regimen of linezolid, bedaquiline, levofloxacin, pyrazinamide (PZA) and ethionamide/high dose isoniazid (INH) compared to the conventional empiric injection-based regimen. The secondary aim is to determine if other treatment-related outcomes including adverse events, adherence to treatment, culture conversion, and cure/completion are significantly different in the intervention and conventional arms.

NCT ID: NCT02430506 Completed - Tuberculosis Clinical Trials

A Study to Evaluate Safety and Immunogenicity of AERAS-402 Administered in HIV-negative, BCG-vaccinated, QFT (+) and (-) Adults Without Evidence of TB

C-012-402
Start date: September 2008
Phase: Phase 1
Study type: Interventional

The available live tuberculosis vaccine Bacillus Calmette-Guérin (BCG) provides incomplete protection against pulmonary tuberculosis. For unknown reasons, a BCG revaccination or "booster", while not toxic, does not provide much additional protection. AERAS-402 presents tuberculosis antigens in the setting of a new, live, replication deficient adenovirus vaccine that may increase T cell immunity and thus protection from tuberculosis. Since BCG-vaccinated individuals are the population for which AERAS-402 might be indicated, AERAS-402 will be administered to individuals in Kenya who have already been vaccinated with BCG.